Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

October 30, 2025

Conditions

AML

Interventions

DRUG

ZE46-0134 or placebo

The patients will receive ZE46-0134 or placebo

DRUG

Rabeprazole, 20mg oral

Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered

DRUG

Itraconazole (200 mg)

Itraconazole 200 mg BID

Trial Locations (1)

Linear Clinical Research Ltd, Perth